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Introduction
From ‘elixir of the life’ to the first cause of aging and 
death, the history of oxygen in modern science and medi-
cine is a fascinating example of controversial hypotheses, 
uncertain findings and wrong theories. The debate con-
tinues, especially in critically ill patients who frequently 
receive oxygen supplementation for preventing or treat-
ing tissue hypoxia. In these patients, the appropriate oxy-
gen dose (i.e. quantity and duration) remains unclear and 
may substantially vary in specific sub-populations. We 
present a brief state-of-the-art update on oxygen ther-
apy in emergency, intensive care and non-intensive care 
settings.
Although the rationale for using oxygen therapy was 
not well developed nor supported by convincing data, 
administering oxygen to non-hypoxaemic patients pre-
senting to the emergency department with acute medical 
emergencies was a common practice. This led researchers 
to conduct several randomized controlled trials (RCTs) 
to determine the efficacy and safety of oxygen therapy in 
this context.
Oxygen therapy in acute stroke
There are six RCTs that examined the effect of oxygen 
therapy on mortality and physical function outcomes 
[1]. The largest was the stroke oxygen study  (SO2S) rand-
omized clinical trial [2] which randomized 8003 patients 
with acute ischaemic stroke to one of three arms: con-
tinuous oxygen, nocturnal oxygen or no oxygen [2]. Oxy-
gen administration did not improve the modified Rankin 
scale (mRS) scores in patients with acute stroke [odds 
ratio (OR) 0.97, 95% CI 0.89–1.05]. Similarly, when the 
total body of evidence was evaluated across six RCTs, 
oxygen therapy did not improve physical function (mRS 
score) in patients with stroke (proportional OR 1.02, 95% 
CI 0.93–1.12) [1]. Different thresholds for oxygen ther-
apy ranged between 30% and 100% oxygen; therefore, a 
threshold for benefit or harm could not be determined 
without an individual patient data meta-analysis.
Oxygen therapy in cardiac ischaemia and cardiac 
arrest
The rationale for oxygen therapy in non-hypoxaemic 
patients with cardiac ischaemia is to decrease the acute 
ischaemic injury and the infarct area [3]. Although 
prominent international guidelines recommended using 
oxygen in patients with cardiac ischaemia, the recom-
mendations were not supported by convincing evidence. 
Several studies showed that hyperoxaemia was associated 
with coronary vasoconstriction and reduced myocardial 
oxygen consumption [4]. Aiming to inform clinical prac-
tice, a landmark RCT (DETO2X-AMI) randomized 6629 
non-hypoxaemic patients with acute myocardial infarc-
tion to receive either continuous supplemental oxygen or 
no oxygen [5]. Oxygen therapy did not reduce mortality 
or re-hospitalization. The main limitation of this trial is 
imprecision as the sample size was not powered to firmly 
exclude harm. A recent systematic review identified six 
RCTs (7778 patients) in a cardiac ischaemia population, 
and a single RCT (17 patients) in cardiac arrest [1]. When 
the effect on mortality was evaluated across all trials, 
oxygen therapy did not improve survival (RR 1.13, 95% 
CI 0.83–1.55); of note, the point estimate showed a 13% 
increase in mortality, and the CI could not exclude a 55% 
increase in mortality.
Recent guidelines issued a strong recommendation 
against using oxygen therapy in non-hypoxaemic patients 
[peripheral oxygen saturation  (SpO2) ≥ 93%] with car-
diac ischaemia or stroke. In addition, they issued a strong 
recommendation for discontinuing oxygen when  SpO2 
≥ 96% [6].
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Non‑intensive care patients
Oxygen supplementation is widely used in hypoxic 
patients admitted to general wards, frequently without 
targeted prescription [7]. Although the disease severity 
and the oxygen concentration used are lower, it is plausi-
ble that inappropriate oxygen therapy may cause negative 
effects similar to those observed in critically ill patients. 
In addition, in general wards the monitoring of oxygen 
levels is commonly less precise than in patients admitted 
to intensive care unit (ICU). Therefore, the exposure to 
hypoxia and hyperoxia may be even more frequent and 
uncontrolled. Unfortunately, few data are available on 
oxygen therapy in this setting, particularly on adverse 
effects related to possible exposure to hyperoxia. Inter-
estingly, a recent retrospective single-centre cohort study 
showed that early hyperoxaemia compared to normox-
aemia was associated with larger in-hospital mortal-
ity and late ICU transfer in patients admitted to general 
wards. Moreover, as in critically ill patients, the total oxy-
gen exposure (area under the curve of  PaO2 levels) was 
related to occurrence of new respiratory, hepatic and 
renal dysfunctions [8].
Oxygen therapy in ICU patients
Oxygen is the most common drug used in the ICU and 
often administrated liberally to give a margin of safety 
against life-threatening hypoxia. The life-saving proper-
ties of oxygen therapy in critically ill patients with hypox-
aemic respiratory failure seem to have overshadowed 
the awareness of serious adverse events (SAEs) caused 
by oxygen. Emerging evidence points towards a reduced 
mortality in acutely ill adults treated with a conservative 
oxygen strategy compared with a liberal oxygen therapy 
[1]. Noteworthy, a single-centre RCT [9] provided 32% 
of the weight in the mortality analysis in this recent sys-
tematic review and meta-analysis [1], but stopped early 
after a non-scheduled interim analysis. Adding to the 
evidence, the HYPERS2S trial [10], a two-by-two facto-
rial multicentre RCT, found a higher risk of SAEs with 
hyperoxaemia and was also terminated early. In contrast, 
a pilot RCT showed no difference in mortality between 
conservative versus liberal oxygenation targets for 
mechanically ventilated patients [11]. Therefore, to what 
degree hyperoxaemia affects mortality in the ICU popu-
lation remains uncertain.
We await the results of several studies in the ICU. The 
largest multicentre RCT in mechanically ventilation 
patients, the ICU-ROX trial (ACTRN12615000957594) 
completed recruitment (1000 patients) in November 
2018, and the results are expected later in 2019. Addi-
tionally, the LOCO2 trial (NCT02713451) stopped 
recruiting and the results are expected soon. The HOT-
ICU trial (NCT03174002), which is focused on patients 
with hypoxaemic respiratory failure, has randomized 
over half of the planned 2928 patients and is still ongoing 
(Table 1).
Undoubtedly, the overall body of evidence supports 
conservative use of oxygen, but the question remains as 
to how conservative the oxygen therapeutic goals should 
be. Table 1 provides an overview of how conservative the 
oxygenation targets is in the ICU RCTs. Until the results 
of ongoing trials are available, the optimal target of oxy-
gen therapy in the ICU population is unknown.
Table 1 How conservative is the oxygenation targets in the ICU trials?
ARDS acute respiratory distress syndrome, ICU intensive care unit, PaO2 partial pressure of arterial oxygen, SpO2 peripheral oxygen saturation
RCTs Status Number 
of patients 
recruited
Inclusion criteria Oxygen target(s) 
in the conservative 
group
Girardis [9] Terminated after an unplanned 
interim analysis
434 out of 660 Expected length of stay in the ICU 
of 72 h
SpO2 up to 98%
PaO2 70–100 mmHg
Asfar [10] Terminated after a planned interim 
analysis
442 out of 800 Mechanical ventilation and septic 
shock
SpO2 up to 97%
Panwar [11] Completed 103 Mechanical ventilation SpO2 up to 92%
ICU-ROX (ACTRN12615000957594) Completed but no results reported 
yet
1000 Mechanical ventilation SpO2 91–96%
LOCO2 (NCT02713451) Active, not recruiting 205 out of 850 ARDS according to the Berlin 
definition
PaO2 55–70 mmHg
SpO2 88–92%
HOT-ICU (NCT03174002) Recruiting 1504 out of 2928 FiO2 at least 0.50 or at least 10 L 
per minute in an open system
PaO2 60 mmHg
ICU-Conservative O2 trial 
(EUDRACT 2018-002525-35)
Starts recruiting in May 2019 Expected 1000 Mechanical ventilation and 
expected length of stay in the 
ICU of 72 h
SpO2 up to 98%
PaO2 70–100 mmHg
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